

#### Media Release

Mumbai, 12th August 2017

QUARTERLY CONSOLIDATED NET PROFIT OF ₹ 220.19 MILLION, UP 29%

QUARTERLY CONSOLIDATED EBIDTA OF ₹ 363.37 MILLION, UP 35%

Quarterly Consolidated Revenue of ₹877.56 Million, Up 28%

QUARTERLY STANDALONE NET PROFIT OF ₹ 231.82 MILLION, UP 29% \*

QUARTERLY STANDALONE EBIDTA OF ₹ 357.59 MILLION, UP 34% \*

Quarterly Standalone Revenue of ₹821.39 Million, Up 20% \*

\* The standalone financial results for the previous year quarter includes revenue/ expenses from imaging services

Above comparative percentages are as to the previous financial quarter

Thyrocare Technologies Limited (the "company") today reported its financial performance for the quarter ended June 30, 2017. The pathology business has grown at 27% over the same period previous year. The radiology business has grown at 33% over the same period previous year.

Beginning 1 April 2017, the Company has for the first time adopted Indian Accounting Standards (IndAS) with a transition date of 1 April 2016. Accordingly these unaudited standalone/ consolidated financial results have been prepared in compliance with IndAS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncement generally accepted in India. The reconciliation between standalone/ consolidated financial results under previous Indian GAAP and IndAS for the quarter ended 30 June 2016 is reported in the notes to the quarterly financial statement.



# **Media Release**

The highlights of the unaudited quarterly financial results as compared to the previous year same quarter are :

# CONSOLIDATED FINANCIAL PERFORMANCE

(Rs in million)		3 Months ended 30th June 2016	% change w.r.t previous financial quarter
Revenue from operations	877.56	687.45	28%
EBIDTA	363.36	268.66	35%
Profit after tax	220.19	170.78	29%
EBITDA margins	41%	39%	
Earnings Per Share (of Rs. 10/- each) (not an	nualised):		
Basic	4.33	3.17	
Diluted	4.32	3.17	

# STANDALONE FINANCIAL PERFORMANCE

(Rs in million)	3 Months ended 30th June 2017	3 Months ended 30th June 2016	% change w.r.t previous financial quarter
Revenue from operations EBIDTA Profit after tax	821.39 357.58 231.82	682.66 266.08 179.90	20% 34% 29%
Revenue from operations (adjusted)# EBIDTA (adjusted)# EBITDA margins (adjusted)#	821.39 357.58 44%	645.17 262.50 41%	27% 36%

<sup>#</sup>figures of the previous year quarter adjusted for the imaging services revenue and associated cost thereof.



#### Media Release

## DISCLAIMER

This media release is for information purposes only and it contains general background information about the company's activities. The company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This media release comprises information given in summary form and does not purport to be complete. This media release should not be considered as a recommendation to any investor to purchase the equity shares of the company. This media release includes statements that are, or may be deemed to be, "forward-looking statements". By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the company will be achieved. The past performance is not indicative of future results.

### **Registered Office**;

D/37-1, TTC MIDC, Turbhe, Navi Mumbai – 400703

CIN: U85110MH2000PLC123882